AIP Form 4: COO Laurent Moll Disposes of 12,978 Shares in Sept 2025
Rhea-AI Filing Summary
Arteris, Inc. (AIP) insider Form 4 summary: The company's Chief Operating Officer, Laurent R. Moll, reported multiple sales of common stock in early September 2025 executed pursuant to a 10b5-1 trading plan adopted March 12, 2025. On 09/05/2025 she sold 4,698 shares at a weighted average price of $8.8045, reducing her beneficial ownership to 394,681 shares. On 09/08/2025 she sold 8,129 shares at a weighted average price of $8.7434, reducing beneficial ownership to 386,552 shares. On 09/09/2025 she sold 151 shares at $8.61, leaving 386,401 shares beneficially owned. The Form 4 was signed by an attorney-in-fact.
Positive
- Trades executed under a 10b5-1 plan, which provides an affirmative defense under Rule 10b5-1 and supports compliance with insider trading rules
- Detailed pricing disclosure with weighted average sale prices and an offer to provide per-trade price breakdowns upon request
- Reporting person remains a substantial holder with 386,401 shares beneficially owned after the reported sales
Negative
- Reported reduction in beneficial ownership totaling 12,978 shares sold across three transactions
- Sales over consecutive days (09/05/2025–09/09/2025) which could attract investor attention despite being under a trading plan
Insights
TL;DR: Insider sales under a 10b5-1 plan reduced the COO's holdings by 13,0?78 shares over three days; the transactions are routine disclosures.
The filings show structured sales executed under a pre-established 10b5-1 trading plan, indicating the reporting person did not trade opportunistically on undisclosed events within the plan's parameters. Total disclosed disposals equal 12,978 shares across 09/05/2025–09/09/2025 at weighted average prices around $8.61–$8.8045, leaving 386,401 shares beneficially owned. From a market-impact perspective these are modest volumes relative to company-wide float (float not provided), so the sales are informative but not necessarily material to valuation on their own.
TL;DR: Transactions documented under a 10b5-1 plan and signed by attorney-in-fact comply with standard disclosure rules.
The Form 4 explicitly notes the trades were pursuant to a 10b5-1 plan adopted March 12, 2025, and includes weighted-average price disclosures and an offer to provide per-trade pricing details. The signature by an attorney-in-fact and the inclusion of explanatory footnotes reflect attention to SEC reporting requirements. No indications of amendments or corrective disclosure are present in the provided content.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 151 | $8.61 | $1K |
| Sale | Common Stock | 8,129 | $8.7434 | $71K |
| Sale | Common Stock | 4,698 | $8.8045 | $41K |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 12, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.69 to $8.93 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.54 to $8.97 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
